CINGW
Cingulate Inc. WarrantsKey Statistics
About Cingulate Inc. Warrants
Cingulate Inc. Warrants offer a compelling investment opportunity tied to a progressive biopharmaceutical company committed to developing innovative therapies for Attention Deficit Hyperactivity Disorder (ADHD) and related disorders. The firm is advancing its lead product aimed at improving treatment efficacy and patient tolerability, thereby addressing significant unmet needs within a rapidly expanding market. With a robust development pipeline and strategic initiatives aimed at scaling operations, Cingulate Inc. is poised for growth, making it an attractive prospect for institutional investors focused on healthcare advancements.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-8.52M |
| EBITDA | $-24.47M |
| Operating Margin | 0.00% |
| Return on Equity | -198.70% |
| Return on Assets | -66.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.69 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $14.21M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CINGW and any ticker you trade — then tracks every position and per-strategy win rate.